AbstractMicroRNA‐133a (MiR‐133a) is proven to exhibit a decreasing tendency in several cancers, as well as pancreatic cancer. Through the present study, we inspected performance for serum miR‐133a in diagnosing pancreatic cancer. Serum samples were collected from 110 pancreatic cancer and 64 healthy persons. Relative messenger RNA level for miR‐133a in serum specimens was gauged adopting quantitative real‐time polymerase chain reaction (qRT‐PCR), and compared betwixt two groups employing the Student t test. Receiver operating characteristics (ROC) analysis evaluated miR‐133a performance in diagnosing pancreatic cancer. MiR‐133a displayed a declining trend among pancreatic cancer samples, compared to the healthy controls (P < .001). The reduced miR‐133a degree held strong relation to tumor dimension (P = .002), vessel invasion (P = .004), tumor lymph node metastasis stage (P = .002), and lymph node metastasis (P < .001). In addition, ROC analysis demonstrated that the area under the curve value was 0.893, accompanied by a sensitivity of 90.6% and a specificity of 87.2%, revealing fine execution for serum miR‐133a in diagnosing cancer. The downregulation of miR‐133a might posse
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً